Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta, Prometheus Close Deal for miRNA Dx Market Rights


Rosetta Genomics this week announced that its previously announced license and collaboration deal with Prometheus Laboratories has closed.

The deal, unveiled earlier this month, gives Prometheus the US market rights to Rosetta's three microRNA-based diagnostics, including miRview Meso, which differentiates lung cancer from mesothelioma; miRview Mets, which is designed to determine the source of cancers of unknown primary origin; and miRview Squamous, which is designed to differentiate squamous from non-squamous non-small cell lung cancer (see RNAi News, 4/16/2009).

As part of the deal, Rosetta and Prometheus will also jointly develop two additional miRNA-based gastroenterology diagnostics.

The companies also said that Prometheus' planned purchase of 2 million shares of Rosetta at $4 per share has been completed.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.